These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34932096)

  • 1. Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases.
    Wallace ZS; Sparks JA
    JAMA; 2021 Dec; 326(23):2370-2372. PubMed ID: 34932096
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply.
    Syversen SW; Bolstad N; Haavardsholm EA
    JAMA; 2021 Sep; 326(11):1069-1070. PubMed ID: 34546304
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    Serkland TT; Skrede S; Berg JA
    JAMA; 2021 Sep; 326(11):1068-1069. PubMed ID: 34546308
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    Le Tilly O; Paintaud G; Ternant D
    JAMA; 2021 Sep; 326(11):1069. PubMed ID: 34546307
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    Papamichael K; Dubinsky MC; Cheifetz AS
    JAMA; 2021 Sep; 326(11):1067. PubMed ID: 34546306
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.
    Ribaldone DG; Saracco GM; Astegiano M; Pellicano R
    Aliment Pharmacol Ther; 2018 Feb; 47(3):448-449. PubMed ID: 29314133
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.
    Gibson DJ; Ward MG
    Aliment Pharmacol Ther; 2019 Mar; 49(6):816-817. PubMed ID: 30811645
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease.
    Orfanoudaki E; Foteinogiannopoulou K; Theodoraki E; Koutroubakis IE
    Inflamm Bowel Dis; 2020 May; 26(6):e50. PubMed ID: 32206807
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
    Yanai H; Dotan I
    J Crohns Colitis; 2019 Apr; 13(5):539-540. PubMed ID: 30535008
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.
    Amiot A; Hulin A; Belhassan M; Andre C; Gagniere C; Le Baleur Y; Farcet JP; Delchier JC; Hüe S
    Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):90-8. PubMed ID: 26138132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
    Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
    Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy.
    Headlam J; Ford AC; Gracie DJ
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1638. PubMed ID: 28529166
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.
    Deora V; Kozak J; El-Kalla M; Huynh HQ; El-Matary W
    Acta Paediatr; 2017 Nov; 106(11):1863-1867. PubMed ID: 28779489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE.
    Queiroz NSF; Teixeira FV; Parra RS; Kotze PG
    Arq Gastroenterol; 2020; 57(4):507-510. PubMed ID: 33331484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive.
    Steenholdt C
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):597-598. PubMed ID: 29555230
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring countering the effect of anti-infliximab antibodies.
    Hooijberg F; Wolbink G
    Lancet Rheumatol; 2024 Apr; 6(4):e193-e194. PubMed ID: 38402892
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.
    Wong U; Cross RK
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1039-1046. PubMed ID: 28876147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: infliximab trough cut-off for perianal Crohn's disease - another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle.
    Mitrev N; Kariyawasam V; Leong RW
    Aliment Pharmacol Ther; 2017 May; 45(9):1279-1280. PubMed ID: 28370040
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
    Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
    Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.